Skip to Content

Yaz Approval History

Yaz (drospirenone and ethinyl estradiol) is a combination oral contraceptive indicated for prevention of pregnancy in women who elect to use an oral contraceptive, treatment of symptoms of premenstrual dysphoric disorder and for the treatment of moderate acne vulgaris.

Development History and FDA Approval Process for Yaz

Jan 30, 2007Approval FDA Approves New Indication for Yaz to Treat Acne
Oct  4, 2006Approval Yaz Acne - Treatment for Prevention of Pregnancy, Premenstrual Dysphoric Disorder
Mar 17, 2006Approval Yaz Berlex, Inc. - Treatment for Prevention of Pregnancy
Jan 25, 2006FDA Clarifies Status of Yaz PMDD Application
Dec  9, 2005FDA Extends Review Period of New Drug Application for Oral Contraceptive Yaz to First Quarter 2006
Nov 18, 2004Berlex Receives Approvable Letter From FDA on the Company's Second Oral Contraceptive Containing Drospirenone

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.